...
首页> 外文期刊>Pharmaceutical Biology >Effects of huoxin formula on the arterial functions of patients with coronary heart disease
【24h】

Effects of huoxin formula on the arterial functions of patients with coronary heart disease

机译:活血方对冠心病患者动脉功能的影响。

获取原文
           

摘要

Context: Huoxin formula is a Traditional Chinese Medicine for coronary heart disease (CHD) treatment. Objective: To explore the therapeutic mechanism of the Huoxin formula on arterial functions in CHD patients. Materials and methods: Fifty-eight CHD patients receiving cardiovascular drugs including β-receptor blocker, statins, and antiplatelet medications or others were randomized into intervention [additionally 13.5?g Huoxin formula granules dissolved in 150?mL warm water per time, twice a day (n?=?30)] and control [only cardiovascular drugs (n?=?28)] groups. Serum biomarkers (hs-CRP, IL-18, IL-17, TNF-α, MMP-9), and cardiovascular indicators of the common and internal carotid arteries (ICAs) were monitored before and after the treatments. Results: After 3 months of treatment, the increases of intima-media thicknesses (IMT) of the left and right common carotid arteries (CCAs) as well as of the left and right ICAs and the increases of the left and right cardio-ankle vascular index were all significantly (all p??0.001) less in the intervention than in control group (all p??0.001). Serum concentrations reductions of hs-CRP, IL-18, IL-17 and MMP9 (all p??0.001) levels were higher in the intervention compared to the control group, which correlated with the changes of left ICA (hs-CRP: r?=?0.581, p?=?0.009; IL-18: r?=?0.594, p?=?0.007; IL-17: r?=?0.575, p?=?0.006). Discussion and conclusion: Since the Huoxin formula improved arterial functions and reduced inflammatory factor activities in CHD patients, a large-scale clinical trial is warranted.
机译:背景:活心方是一种治疗冠心病(CHD)的中药。目的:探讨活心方对冠心病患者动脉功能的治疗机制。材料和方法:将58名接受心血管药物(包括β受体阻滞剂,他汀类药物和抗血小板药物或其他药物)的冠心病患者随机分为干预组[此外,每天两次将13.5?g霍辛配方颗粒溶于150?mL的温水中,每天两次(n?=?30)]和对照组[仅心血管药物(n?=?28)]组。在治疗之前和之后,监测血清生物标志物(hs-CRP,IL-18,IL-17,TNF-α,MMP-9)以及颈总动脉和颈内动脉的心血管指标。结果:治疗3个月后,左右颈总动脉(CCA)和左右ICA的内膜中层厚度(IMT)增加,左右心踝血管的增加干预组的所有指标均明显低于对照组(均P <0.001)(均P <0.001)。干预组的血清hs-CRP,IL-18,IL-17和MMP9浓度降低幅度均高于对照组(均p <0.001),这与左ICA(hs-CRP: r = 0.581,p = 0.009; IL-18:r = 0.594,p = 0.007; IL-17:r = 0.575,p = 0.006)。讨论与结论:由于霍欣配方改善了冠心病患者的动脉功能并降低了其炎症因子活性,因此有必要进行大规模的临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号